Screening and Resistance
Hub), has received £2.5million to establish a national resource which will initially be dedicated to supporting and accelerating vital COVID-19 antiviral innovation drug translation.
The facility is funded by £2m from medical research charity LifeArc, with additional funding from the Medical Research Council. CVR CRUSH will be delivered by the University of Glasgow in collaboration with partners LifeArc and the University of Dundee Drug Discovery Unit.
Global control of the COVID-19 pandemic is dependent on the availability of effective medical treatments and vaccines. CVR CRUSH will help support the global scientific effort against the disease by providing a fully integrated hub for pre-clinical drug screening and resistance assays for SARS-CoV-2, the virus that causes COVID-19, as well as providing the same services for other dangerous and deadly viruses in high containment facilities.
Glasgow University science hub established to screen Covid-19 drugs
A coronavirus sample is held at a laboratory in Glasgow (Andrew Milligan/PA)
A £2.5 million science hub is to be established at the University of Glasgow to screen treatments for Covid-19.
Crush (Covid-19 Drug-Screening and Resistance Hub) will investigate promising drugs for the virus.
It will also provide drug screening for other dangerous and deadly viruses in its high containment facilities.
Scientists at the hub will look to identify any possible drug and immune-resistant virus variants.
Research charity LifeArc has given £2 million to the project, with additional funds provided by the Medical Research Council.
Glasgow University science hub set up to screen Covid-19 drugs A new science hub is to be created at Glasgow University to screen treatments for coronavirus. The £2.5 million facility, named Crush (Covid-19 Drug-Screening and Resistance Hub), will investigate promising drugs for the virus. It will also provide drug screening for other dangerous and deadly viruses in its high containment facilities. Scientists at the hub will look to identify any possible drug and immune-resistant virus variants. Research charity LifeArc has given £2 million to the project, with additional funds provided by the Medical Research Council. It will be based at the MRC-University of Glasgow Centre for Virus Research (CVR) in partnership with the University of Dundee Drug Discovery Unit.
Biospring Partners Expands Team and Announces its Advisory Board
Share Article
Biospring Partners has appointed Drew Pearson as Head of Portfolio Management, and the firm has added several industry leaders to its Advisory Board.
Drew Pearson
“I’m excited to be establishing an industry leading Portfolio Management function at Biospring Partners. We will be leveraging best in class systems and processes to optimize Biospring’s management of its investments,” said Drew Pearson. NEW YORK and BOSTON (PRWEB) December 10, 2020
Biospring Partners, growth investors in Life Sciences Technology, is announcing key additions to its team and advisory board.
Drew Pearson has joined Biospring as Head of Portfolio Management. In this role, Drew will lead performance management and value creation across Biospring’s portfolio. Prior to Biospring, Drew spent over twenty years at General Atlantic as Managing Director, He